Intuitive Surgical, Inc. (ISRG)
| Market Cap | 178.44B -15.0% |
| Revenue (ttm) | 10.06B +20.5% |
| Net Income | 2.86B +23.0% |
| EPS | 7.87 +22.6% |
| Shares Out | 355.13M |
| PE Ratio | 63.84 |
| Forward PE | 50.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 527,590 |
| Open | 494.00 |
| Previous Close | 494.02 |
| Day's Range | 494.00 - 506.07 |
| 52-Week Range | 425.00 - 603.88 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 612.40 (+21.88%) |
| Earnings Date | Jan 22, 2026 |
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling,... [Read more]
Financial Performance
In 2025, Intuitive Surgical's revenue was $10.06 billion, an increase of 20.51% compared to the previous year's $8.35 billion. Earnings were $2.86 billion, an increase of 22.97%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ISRG stock is "Buy." The 12-month stock price target is $612.4, which is an increase of 21.88% from the latest price.
News
Intuitive Surgical: Buy The January Selloff
Intuitive Surgical remains a compelling long-term buy despite recent share price weakness and mixed Q4 results. Da Vinci 5 adoption is robust, with 74% YoY system placement growth and expanding FDA-ap...
These Analysts Revise Their Forecasts On Intuitive Surgical After Q4 Results
Intuitive Surgical Inc (NASDAQ: ISRG) reported better-than-expected financial results for the fourth quarter after the market close on Thursday.
More Upside For ISRG Stock?
Intuitive Surgical reported strong Q4 2025 outcomes with adjusted EPS of $2.53, exceeding estimates of $2.26 and increasing by 14.5% from Q4 2024's $2.21. Revenue reached $2.87 billion, a 19% increase...
20 Million Patients Benefit from da Vinci Surgery Globally
Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive's minimally invasive technologies Achievement reflects the dedication of...
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Intuitive Surgical beats quarterly estimates on demand for surgical robots
Intuitive Surgical on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on growing demand for its surgical robots used in minimally invasive procedures.
Intuitive Announces Fourth Quarter Earnings
SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today ...
Polen Focus Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity
Eli Lilly's stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the ...
Is PODD A Better Bet Than ISRG Stock?
PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:
Intuitive Surgical: Buying The Dip On This Wide-Moat Compounder
Intuitive Surgical continues robust double-digit growth, with Q4 2025 revenues up 19% y/y and strong da Vinci 5 adoption. The firm's 2026 procedure growth guidance of 13–15% disappointed versus expect...
Intuitive Surgical, Inc. (ISRG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intuitive Surgical, Inc. (ISRG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today ...
Intuitive Surgical: An Easy 'Buy And Hold' For Long-Term Outperformance
Intuitive Surgical, Inc. dominates surgical robotics with an 80% global share and a robust, recurring-revenue business model anchored by the da Vinci platform. ISRG's installed base and procedure volu...
Is ISRG Stock Still A Buy At $600?
ISRG stock has climbed nearly 40% from its October 2025 lows of approximately $425, currently trading near $590. What has spurred this remarkable rise?
Final Trades: Intuitive Surgical, Dick's Sporting Goods and Toast Inc
The Investment Committee's latest market picks.
Intuitive Surgical: Is The Smart Money Moving In?
Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted p...
Is It Time To Buy Intuitive Surgical Stock?
Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted p...
Fisher, Cohen & Laffont's Robotics Pick Just Triggered A Golden Cross
Robotics just delivered a breakout moment — and it's happening in Intuitive Surgical Inc (NASDAQ: ISRG), a stock already sitting deep inside the portfolios of three billionaire heavyweights.
Intuitive Surgical: Da Vinci Delivers, Double-Digit EPS Growth, Golden Cross
Intuitive Surgical delivered robust Q3 results, with 23% revenue growth and a significant double beat on EPS and revenue. ISRG's valuation remains lofty, trading near fair value despite strong growth ...
Can Intuitive Surgical Still Be A Good Buy?
Intuitive Surgical (ISRG) stock may be a solid investment at this time. Why? Because you're getting high margins – indicative of pricing power and cash generation capability – for a discounted price.
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...
Baron Fifth Avenue Growth Fund Q3 2025 Performance Update
Baron Fifth Avenue Growth Fund gained 5.7% during the third quarter, lagging the 10.5% gain for the Russell 1000 Growth Index and the 8.1% gain for the S&P 500 Index, the Fund's benchmarks. NVIDIA rep...
RiverPark Long/Short Opportunity Fund: Q3 2025 Top And Bottom Performers
GOOG was our top contributor in the quarter, benefiting from accelerating momentum in its core Search and YouTube franchises. We continue to view Alphabet as among the best-positioned secular growth f...
PODD Vs. Intuitive Surgical: This Underdog Might Just Win
When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, ...
Intuitive Surgical Stock To $700?
Intuitive Surgical (ISRG) has been on a powerful run, fueled by rising adoption of its da Vinci robotic systems and steady growth in surgical procedure volumes worldwide. The stock has outpaced both t...